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Epigenetic reprogramming is a feature of many human cancers. In this issue of Cancer Cell, Letouze´ and
colleagues describe DNA hypermethylation in paragangliomas harboring mutations in succinate dehydroge-
nase genes. These tumors accumulate succinate, which inhibits 2-oxoglutarate-dependent histone and DNA
demethylase enzymes, resulting in epigenetic silencing that affects neuroendocrine differentiation.Metabolic rewiring has long been re-
garded as a consequence of malignant
transformation driven by abnormal signal
transduction mediated by oncogenes
and tumor suppressors. The identification
that the metabolite (R)-2-hydroxygluta-
rate [(R)-2HG] plays an oncogenic role in
subsets of gliomas and acute myeloge-
nous leukemia with mutations in isoforms
of isocitrate dehydrogenase (IDH) has
provided direct evidence linking altered
metabolism and cancer and founded the
notion of the ‘‘oncometabolite’’ (Ward
et al., 2010). (R)-2HG is a product of the
neomorphic activities of mutant IDH1/2
and accumulates to millimolar concentra-
tions in IDH-associated gliomas (Dang
et al., 2010). Due to the structural similar-
ity to 2-oxoglutarate (2OG), (R)-2HG
competitively inhibits the 2OG-utilizing
Jumonji C (JmjC)-domain containing his-
tone lysine demethylases and the TET
family of 5-methylcytosine (5mC) hydrox-
ylases, leading to DNA hypermethylation
at CpG islands in promoter regions of
genes involved in cell differentiation (Kim
and DeBerardinis, 2013).
The Krebs cycle enzymes succinate
dehydrogenase (SDH) and fumarate
hydratase (FH) are tumor suppressors
whose loss-of-function mutations predis-
pose to familial cancer syndromes (Frezzaet al., 2011). SDH and FH inactivation
results in a blockade of Krebs cycle,
impaired respiration, and abnormal accu-
mulation of their substrates succinate and
fumarate, respectively. Both metabolites
are also inhibitors of 2OG-dependent
dioxygenases, particularly the hydroxy-
lases for the transcription factor hypoxia-
inducible factor (HIF), resulting in
HIF-dependent activation of a ‘‘pseudo-
hypoxic’’ response characterized by
enhanced angiogenesis and increased
anaerobic metabolism (Frezza et al.,
2011). In the case of fumarate, the metab-
olite is also an endogenous electrophile
and can chemically modify cysteine
residues in Kelch-like ECH-associated
protein 1, leading to constitutive (and
potentially oncogenic) activation of tran-
scription factor nuclear factor erythroid
2-related factor 2 (Adam et al., 2011; Ooi
et al., 2011). Until recently, HIF activation
by fumarate and succinate has been the
only mechanistic link to oncogenesis that
hasbeendescribed inFH andSDHmutant
cancer models (Pollard et al., 2007; Selak
et al., 2005). However, at least in the
context of FH-deficiency, a causal role
for HIF in tumorigenesis is questionable
(Adamet al., 2011), and the quest for other
oncogenic drivers inSDH- andFH-associ-
ated malignancy continues. Recent re-ports by Killian et al. (2013) and Letouze´
et al. (2013; in this issue of Cancer Cell)
both demonstrate that, similarly to (R)-
2HG, succinate can also remodel the epi-
genome and alter gene expression.
SDHmutations occur frequently in par-
aganglioma (PGL), pheochromocytoma
(PCC), gastrointestinal stromal tumor
(GIST), as well as in renal carcinoma (Kill-
ian et al., 2013). GIST tumors can alterna-
tively be driven by mutations in signal
transduction kinases. Killian et al. (2013)
compared the methylation profiles of
GISTs with mutations in either SDH or
KIT tyrosine kinase and uncovered
marked global hypermethylation in the
SDH versus KIT mutant subgroup.
Further examination of a PGL/PCC cohort
showed a similar hypermethylation phe-
notype in SDH mutant tumors compared
to SDH-wild-type reference tissues.
Bioinformatic analyses of methylomes
from developmentally distinct tumors
including GIST, PGL, PCC, and gliomas
revealed comparable methylation signa-
tures in those harboring SDH and IDH
mutations (Killian et al., 2013).
Letouze´ et al. (2013) classified a
large PGL/PCC cohort based on DNA
methylation and obtained three stable
clusters. Strikingly, a distinct subgroup
characterized by the presence of a23, June 10, 2013 ª2013 Elsevier Inc. 709
Figure 1. Epigenetic Reprogramming by Oncometabolites
Mutations in the metabolic enzymes isocitrate dehydrogenase (IDH)-1 and -2, succinate dehydrogenase (SDH), and fumarate hydratase (FH) lead to abnormal
accumulation of (R)-2-hydroxyglutarate [(R)-2HG], succinate, and fumarate, respectively. Their accumulation inhibits the activities of 2-oxoglutarate (2OG)-depen-
dent dioxygenases, including the TET family of DNAmodifying enzymes and the JmjCdomain-containing histone lysine demethylases (KDMs). Subsequent epige-
netic alterations result in cell differentiation arrest and promotemalignant transformation. Thus, epigenetic modification, through the action of oncometabolites, is
a shared feature among IDH-, SDH-, and FH-associated cancers. SUCC, succinate; FUM, fumarate; Mal, malate; mIDH1/2, mutant IDH1/2; Me, methyl group.
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Previewshypermethylator phenotype contained 16
of 17 samples that harbor SDHmutations.
The prevailing model is that accumulation
of succinate in these tumors inhibits 2OG-
dependent oxidative demethylation in a
manner analogous to the action of (R)-
2HG, giving rise to DNA hypermethyla-
tion. Integration of methylation and gene
expression data revealed, whereas most
hypermethylated CpG sites had no func-
tional consequences, there were 191
genes that showed correlated levels of
hypermethylation and downregulation
(Letouze´ et al., 2013).
SDH- and VHL-related tumors share
some similar features in gene expression
profiles, possibly due to activation of
HIF-orchestrated hypoxia-related genes.
Nonetheless, SDH- and VHL-associated
PGL/PCC from the cohort studied were
clustered as two distinct gene-expres-
sion subgroups, suggesting that epige-
netic remodelling plays a major role in
the transcriptional divergence of these
two tumor subclasses. Intriguingly, the
only tumor sample in the hypermethy-
lated PGL/PCC subgroup without SDH
mutations was shown to harbor germ-
line inactivating FH mutations. This
finding corroborates recent evidence
demonstrating that fumarate-mediated
inhibition of TET and KDM enzymes
alters histone and DNA methylation pat-710 Cancer Cell 23, June 10, 2013 ª2013 Elsterns (Xiao et al., 2012) and raises the
necessity to test FH-associated neo-
plasms for epigenetic abnormalities in
future studies.
Consistent with the findings by Killian
et al. (2013), Letouze´ et al. (2013)
compared the CpG methylator pheno-
types between SDH/FH mutant PGL/
PCC and IDH mutant gliomas and identi-
fied significant overlap in hypermethy-
lated CpG sites. Particularly, 17 genes
were concordantly hypermethylated and
downregulated in both tumor groups.
The connection in methylation profiles
between the SDH, FH, and IDH mutant
tumors may reflect a similar inhibitory
role for succinate, fumarate, and (R)-
2HG (see Figure 1), whereas the differ-
ences may partly be attributed to the
variable susceptibilities of the panoply of
2OG-dependent oxygenases to the three
oncometabolites.
All of the SDH mutant PGL/PCC in this
study exhibited low 5-hydroxymethylcy-
tosine (5hmC) levels by immunohisto-
chemistry analyses, and the majority
also showed elevated histonemethylation
at H3K27, supporting the hypothesis
that succinate inhibits TET- and KDM-
mediated demethylations. Consistently,
Sdhb/ mouse chromaffin cells dis-
played higher 5mC/5hmC ratios com-
pared to wild-type cells, which could beevier Inc.reversed by the addition of exogenous
2OG to the culture medium. Importantly,
the hypermethylated genes detected in
these cells significantly overlapped with
those identified in SDH mutant PGL/PCC.
The SDH enzyme complex comprises
four subunits (SDHA, SDHB, SDHC, and
SDHD). Although mutations in all subunits
occur in cancer, tumors harboring muta-
tions in the catalytic subunit SDHB are
particularly malignant and associated
with a higher risk of metastasis (Frezza
et al., 2011). Letouze´ et al. (2013) showed
that the mean methylation levels across
all CpG sites are higher in SDHB-mutated
PGL/PCC than other SDH mutant PGL/
PCC. It is possible that the loss of SDHB
function results in bona fide inactivation
of the SDH complex, whereas reductions
of enzyme activity through mutations in
other subunits are not as complete.
Consequently, there might be higher
succinate accumulation and stronger in-
hibition of demethylation in SDHBmutant
tumors. Although the differences in succi-
nate levels could not be demonstrated
from the SDH mutant PGL/PCC cohort,
the heterogeneity of tumor samples may
preclude accurate analyses and further
investigations employing cell culture
models could be more informative. Two
of the most significantly silenced
genes in the hypermethylated subgroup,
Cancer Cell
PreviewsPNMT and KRT19, are respectively
involved in neuroendocrine differentiation
and epithelial-to-mesenchymal transition
(EMT). Interestingly, despite exhibiting a
decreased growth rate similar to the
Fh1/ mouse embryonic fibroblasts, the
Sdhb/ chromaffin cells showed mark-
edly increased migratory capacities,
potentially reflecting epigenetic deregula-
tion of EMT genes and the aggressive
nature of SDHB-related PCC/PGL.
Recently, inhibitors that specifically
target mutant IDH1 and IDH2 have been
reported. Such inhibitors could reverse
(R)-2HG-mediated epigenetic deregula-
tion, induce cell differentiation, and sup-
press the growth of IDH mutant tumor
cells (Kim and DeBerardinis, 2013).
Letouze´ et al. (2013) showed that tran-
sient treatment with a DNA methyltrans-
ferase inhibitor repressed the migration
capacities of Sdhb/ cells, implicating
the possibility of epigenetic targeting in
SDH-related tumors. However, succinate
and fumarate accumulation exert variousnonepigenetic cellular impacts, and, to
achieve therapeutic efficacy, a synergistic
lethality approach is probably desired.
Nonetheless, the emergence of epigenet-
ically silenced gene sets may serve as
useful biomarkers for early detection of
cancers characterized by Krebs cycle
defects.REFERENCES
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Activated STAT3 and increased expression of the histone methyltransferase EZH2 are independently asso-
ciated with the most malignant subset of gliomas. In this issue of Cancer Cell, Kim and colleagues discover
that EZH2 enhances STAT3 activation by trimethylating lysine180 in STAT3 and does so preferentially in
glioma stem-like cells.Presuming that cancer stem cells are
responsible for therapeutic resistance in
cancer patients, the discovery of the
molecular differences that drive cancer
stem cell phenotypes holds significant
value for improving therapy. More valu-
able still would be the ability to selectively
inhibit these molecular drivers of stem-
ness. In this issue of Cancer Cell, Kim
et al. (2013) employ cultures of glioma
stem-like cells (GSCs) and their isogenic
bulk tumor cells along with intracranial
xenografts and come one step closer to
achieving this ambitious goal.Mutation or overexpression of en-
hancer of Zeste homolog 2 (EZH2) can
drive the clonal expansion of leukemias
and the growth of solid cancers, though
individual EZH2 alterations follow diver-
gent paths toward malignancy. EZH2 is
most known as an enzymatically active
component of the Polycomb repressive
complex 2 (PRC2), which is responsible
for depositing methyl groups onto lysine
27 (K27) of histone H3 (H3K27). EZH2
plays an important role in maintaining
stem cell function. The most common
EZH2 mutations in cancer occur withinthe SET domain at Y641, which result in
increased trimethylation activity, leading
to an increase in global H3K27me3 levels
in B cell lymphomas (Yap et al., 2011). In
contrast, in breast cancer cells, AKT-
mediated phosphorylation of S21 reduces
EZH2 interaction with histone H3, leading
to a decrease in global H3K27me3 levels
(Cha et al., 2005). In addition, in pediatric
brain tumors, recurrent somatic mutation
of K27 on histone H3 variant H3F3A may
deplete H3K27me3 on canonical H3
indirectly because of increased interac-
tion between mutant H3F3A and EZH2.23, June 10, 2013 ª2013 Elsevier Inc. 711
